@Article{,
AUTHOR = {Alan So, S. Larry Goldenberg, Martin E. Gleave},
TITLE = {Prostate specific antigen: an updated review},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {10},
YEAR = {2003},
NUMBER = {6},
PAGES = {2040--2050},
URL = {http://www.techscience.com/CJU/v10n6/62708},
ISSN = {1488-5581},
ABSTRACT = {Since its discovery in 1979, serum PSA has
revolutionized how physicians manage men with prostate
cancer. PSA screening, although currently under much
debate, has been recommended by most North American
medical bodies, including the Canadian Urological
Association, to be performed as a shared-decision making
process after discussing with patients the pros and cons
of treatment. Although most commonly thought of as a
screening tool, serum PSA has also been used to predict
tumor volume, stage and prognosis in patients before and
after treatment. In this review, we examine PSA testing
and its effectiveness in the diagnosis and management of
prostate cancer. Further, we also evaluate recent literature
regarding the use of PSA derivatives and other prostate
cancer markers, such as proPSA, bPSA, and hk2.},
DOI = {}
}